Stocks · News reference
Eton Pharmaceuticals released preliminary results from a pilot study of ET-700, an investigational extended-release zinc acetate formulation for Wilson disease, showing improved tolerability compared to GALZIN.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Eton Pharmaceuticals exceeded expectations in Q3 2026 with revenues of $57.9M (158% YoY growth) and raised full-year revenue guidance to over $175M with adjusted EBITDA margins above 40%. The company achieved its $200M annualized revenue run-rate target five quarters ahead of schedule, driven primarily by HEMANGEOL sales. Eton is preparing for an April 2027 LIBERVANT launch and advancing its pipeline including ASN-001 and ET-900.
Eton Pharmaceuticals announced that its executive leadership team will present at the 2026 Jefferies Global Healthcare Conference in London in November 2026.
Eton Pharmaceuticals reported record third-quarter 2026 revenue of $57.9 million, a 158% year-over-year increase, and raised its full-year 2026 financial guidance.
Filed: 2026-11-05 AccNo: 0001710340-26-000006 Size: 504 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Eton Pharmaceuticals has launched a new development program, ET-900, to evaluate mecasermin injection for the treatment of infantile and epileptic spasms.
Eton Pharmaceuticals has announced it will release its financial results for the third quarter of 2026 on Thursday, November 5, 2026, followed by a conference call and webcast.